CA2987909C - Ketamine transdermal delivery system - Google Patents

Ketamine transdermal delivery system Download PDF

Info

Publication number
CA2987909C
CA2987909C CA2987909A CA2987909A CA2987909C CA 2987909 C CA2987909 C CA 2987909C CA 2987909 A CA2987909 A CA 2987909A CA 2987909 A CA2987909 A CA 2987909A CA 2987909 C CA2987909 C CA 2987909C
Authority
CA
Canada
Prior art keywords
delivery device
transdermal delivery
ketamine
present
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2987909A
Other languages
English (en)
French (fr)
Other versions
CA2987909A1 (en
Inventor
Huadong Tang
Hock S. Tan
Michael MAYERSOHN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenox Pharmaceuticals LLC
Original Assignee
Mayersohn Michael
Shenox Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayersohn Michael, Shenox Pharmaceuticals LLC filed Critical Mayersohn Michael
Publication of CA2987909A1 publication Critical patent/CA2987909A1/en
Application granted granted Critical
Publication of CA2987909C publication Critical patent/CA2987909C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2987909A 2015-06-27 2016-06-27 Ketamine transdermal delivery system Active CA2987909C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562185573P 2015-06-27 2015-06-27
US62/185,573 2015-06-27
PCT/US2016/039601 WO2017003935A1 (en) 2015-06-27 2016-06-27 Ketamine transdermal delivery system

Publications (2)

Publication Number Publication Date
CA2987909A1 CA2987909A1 (en) 2017-01-05
CA2987909C true CA2987909C (en) 2022-04-26

Family

ID=57609546

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2987909A Active CA2987909C (en) 2015-06-27 2016-06-27 Ketamine transdermal delivery system

Country Status (9)

Country Link
US (2) US11191734B2 (enExample)
EP (1) EP3297620A4 (enExample)
JP (1) JP6845162B2 (enExample)
KR (1) KR102299359B1 (enExample)
CN (1) CN107847469A (enExample)
AU (1) AU2016288188B2 (enExample)
CA (1) CA2987909C (enExample)
HK (1) HK1248578A1 (enExample)
WO (1) WO2017003935A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140275278A1 (en) 2013-03-15 2014-09-18 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
HRP20211629T1 (hr) 2013-09-13 2022-02-04 National University Corporation Chiba University Primjena r-ketamina i njegove soli kao lijekova
CA2961208A1 (en) 2014-09-15 2016-03-24 Janssen Pharmaceutica Nv Val66met (snp rs6265) genotype specific dosing regimens and methods for the treatment of depression
WO2018091473A1 (en) 2016-11-15 2018-05-24 Klaria Pharma Holding Ab Pharmaceutical formulation
US20200030251A1 (en) * 2017-04-20 2020-01-30 Guangzhou Dazhou Biomedicine Ltd. Transdermal drug delivery system for ketamine
US11179469B2 (en) 2017-04-28 2021-11-23 Nitto Denko Corporation Transdermal absorption preparation
GB201709141D0 (en) 2017-06-08 2017-07-26 Klaria Pharma Holding Ab Pharmaceutical formulation
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
US11491120B2 (en) 2017-11-09 2022-11-08 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
WO2019094596A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
CN107823195A (zh) * 2017-11-24 2018-03-23 无锡市精神卫生中心 R‑氯胺酮在抑郁症急性期治疗中的应用
MX2020006650A (es) 2017-12-22 2020-11-06 Janssen Pharmaceuticals Inc Esketamina para el tratamiento de la depresión.
PL3505157T3 (pl) 2017-12-29 2022-04-11 Celon Pharma S.A. Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie
CN118453559A (zh) 2018-02-15 2024-08-09 国立大学法人千叶大学 炎症性疾病或骨病的预防或治疗剂及医药组合物
DK3784237T3 (da) * 2018-04-25 2024-01-08 Shinkei Therapeutics Inc Indretning til transdermal levering af tetrabenazin
CA3099293A1 (en) 2018-05-04 2019-11-07 Perception Neuroscience, Inc. Methods of treating substance abuse
GB201808462D0 (en) 2018-05-23 2018-07-11 Klaria Pharma Holding Ab Pharmaceutical formulation
US20210308040A1 (en) * 2018-10-26 2021-10-07 Guangzhou Dazhou Biomedicine Ltd. Ketamine oral transmucosal delivery system
CN111346073B (zh) * 2018-12-21 2022-06-10 宜昌人福药业有限责任公司 一种透皮给药的药物组合物及其制备方法和应用
WO2020178653A1 (en) 2019-03-05 2020-09-10 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
BR112021019190A2 (pt) * 2019-04-17 2021-11-30 Lts Lohmann Therapie Systeme Ag Sistema terapêutico transdérmico
EP3725306A1 (en) 2019-04-17 2020-10-21 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system
US11752114B2 (en) 2019-04-17 2023-09-12 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system
CN109966272A (zh) * 2019-04-30 2019-07-05 深圳市泛谷药业股份有限公司 一种氯胺酮透皮贴剂及其制备方法
GB201912505D0 (en) * 2019-08-30 2019-10-16 Klaria Pharma Holding Ab Pharmaceutical formulation
WO2021121366A1 (en) 2019-12-20 2021-06-24 Alar Pharmaceuticals Inc. Long-acting injectable formulations of ketamine pamoate salts
WO2021255522A1 (en) * 2020-06-19 2021-12-23 Guangzhou Dazhou Biomedicine Ltd. Transdermal drug delivery system for ketamine
EP3949956A1 (en) * 2020-08-06 2022-02-09 LTS Lohmann Therapie-Systeme AG Esketamine-suspension-tts
CN117797131A (zh) * 2022-09-30 2024-04-02 宜昌人福药业有限责任公司 S-氯胺酮经皮组合物及其制备方法和应用
CN117797130A (zh) * 2022-09-30 2024-04-02 宜昌人福药业有限责任公司 S-氯胺酮经皮组合物及其制备方法和应用
US12005035B1 (en) * 2023-08-14 2024-06-11 Daniel C. Javitt Compositions and methods for treatment of chronic pain and depression
WO2025037252A1 (en) * 2023-08-14 2025-02-20 Javitt Daniel C Compositions and methods for treatment of chronic pain and depression

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635204A (en) * 1994-03-04 1997-06-03 Montefiore Medical Center Method for transdermal induction of anesthesia, analgesia or sedation
WO1997007750A1 (en) * 1995-08-30 1997-03-06 Weg Stuart L Administration of ketamine to manage pain and to reduce drug dependency
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US6017961A (en) 1999-07-08 2000-01-25 Flores; John Anthony Ketamine and n-butyl-p-aminobezoate in PLO
ES2357808T3 (es) 2001-06-07 2011-04-29 Christine Dr. Sang Tratamiento del dolor neuropático con antagonistas del receptor de n-metil-d-aspartato (nmda).
US20030082225A1 (en) * 2001-10-19 2003-05-01 Mason Paul Arthur Sterile, breathable patch for treating wound pain
US6855735B2 (en) 2002-03-20 2005-02-15 Temple University Of The Commonwealth System Of Higher Education Ketamine treatment of restless legs syndrome
US20050148673A1 (en) 2002-07-11 2005-07-07 Harbut Ronald E. Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition
EP1551393A4 (en) 2002-07-30 2010-06-16 Peter Migaly COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
CA2506615A1 (en) 2002-11-18 2004-06-03 Yaupon Therapeutics, Inc. Analgesic uses of norketamine and ketamine/norketamine prodrugs
US7687080B2 (en) * 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US10172810B2 (en) 2003-02-24 2019-01-08 Pharmaceutical Productions, Inc. Transmucosal ketamine delivery composition
US20040265364A1 (en) 2003-06-25 2004-12-30 Binnur Ozturk Neuropathy cream
US20050222270A1 (en) 2004-02-26 2005-10-06 Olney John W Prolonged administration of NMDA antagonist drug and safener drug to create improved stable neural homeostasis
US8741332B2 (en) 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for dermally treating neuropathic pain
CN101163481A (zh) 2005-03-04 2008-04-16 纽罗赛斯特克公司 改进的加环利定制剂
CN101466364A (zh) 2006-03-22 2009-06-24 纽约大学西奈山医学院 鼻内施用氯胺酮治疗抑郁症
US7645767B2 (en) 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
CN101765582A (zh) 2007-04-26 2010-06-30 奥斯拜客斯制药有限公司 氘标记的氯胺酮
CA2688294C (en) * 2007-06-08 2012-08-07 Dong-Won Kim Matrix-type transdermal drug delivery system and preparation method thereof
JP2011526889A (ja) * 2008-06-30 2011-10-20 アフギン ファーマ，エルエルシー 局所局部的神経作用療法
WO2010036937A1 (en) 2008-09-27 2010-04-01 Taraxos Inc. Topical formulations for treatment of neuropathy
US8394759B2 (en) 2008-11-21 2013-03-12 Cymbiotics, Inc. Transdermal delivery of medicaments with combinations of cetylated fatty ester penetrant complexes
JP2010229045A (ja) * 2009-03-26 2010-10-14 Mikasa Seiyaku Co Ltd 経皮吸収型製剤
US20120225949A1 (en) 2009-08-14 2012-09-06 Demitri Papalos Compositions and methods for treating bipolar disorder
KR101292768B1 (ko) * 2010-04-23 2013-08-05 아이큐어 주식회사 경피 흡수 제제
RU2589692C2 (ru) 2010-06-15 2016-07-10 Грюненталь Гмбх Фармацевтическая комбинация для лечения от боли
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
US9073819B2 (en) 2011-06-30 2015-07-07 University Of South Florida Compositions, methods of use, and methods of treatment
US9724315B2 (en) * 2011-09-30 2017-08-08 Cmpd Licensing, Llc Compounded transdermal pain management
CN104395283A (zh) 2011-10-14 2015-03-04 美国政府健康及人类服务部 (2r,6r)-羟基去甲氯胺酮、(s)-脱氢去甲氯胺酮以及(r,s)-氯胺酮的其他立体异构脱氢和羟基化代谢物在治疗忧郁症和神经性疼痛中的应用
JP2015501652A (ja) 2011-12-14 2015-01-19 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Ｇａｂｒ−ａ２診断
WO2013113690A1 (en) * 2012-01-31 2013-08-08 Grünenthal GmbH Pharmaceutical patch for transdermal administration of (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amine
US20130209585A1 (en) 2012-02-13 2013-08-15 Stanley Kim Topical NMDA Antagonist Formulations for the Treatment of Peripheral Neuropathy
WO2013138322A1 (en) 2012-03-12 2013-09-19 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
JP2015512418A (ja) 2012-03-30 2015-04-27 ザ ジェネラル ホスピタル コーポレイション うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
WO2014020155A1 (en) 2012-08-02 2014-02-06 Clinpharm Reform Gmbh Oral transmucosal adminstration forms of s-ketamine
AU2013305580A1 (en) 2012-08-23 2015-04-09 Stuart L. Weg Anxiolytic composition, formulation and method of use
FR2994844B1 (fr) 2012-08-31 2015-01-02 Assist Publ Hopitaux De Paris Formulation gelifiante a base de ketamine
EA201590697A1 (ru) 2012-10-08 2015-09-30 Окленд Юнисервисиз Лимитед Производные кетамина
US20140275278A1 (en) 2013-03-15 2014-09-18 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
AU2014250756B2 (en) 2013-04-12 2019-03-07 Icahn School Of Medicine At Mount Sinai Method for treating post-traumatic stress disorder
WO2015031410A1 (en) 2013-08-26 2015-03-05 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
HRP20211629T1 (hr) 2013-09-13 2022-02-04 National University Corporation Chiba University Primjena r-ketamina i njegove soli kao lijekova
WO2015051259A1 (en) 2013-10-04 2015-04-09 Impax Laboratories, Inc. Pharmaceutical compositions and methods of use
CA2923064C (en) * 2014-02-20 2016-10-25 Cura Health Inc. Transdermal composition for treating pain
US11207316B2 (en) 2014-05-30 2021-12-28 West Virginia University Ketamine or dextromethorphan formulations and methods of use
EP3179993B1 (en) 2014-08-13 2021-01-20 Janssen Pharmaceutica NV Esketamine for use in a method for the treatment of depression
RU2771275C2 (ru) 2014-11-04 2022-04-29 Аморса Терапьютикс, Инк. Нейро-аттенуирующие кетаминовые и норкетаминовые соединения, их производные и способы их получения
US20180015054A1 (en) 2014-12-31 2018-01-18 Icahn School Of Medicine At Mount Sinai Method of Maintaining the Anti-Depressant Effect of Ketamine With Lithium
WO2016172672A1 (en) 2015-04-24 2016-10-27 Icahn School Of Medicine At Mount Sinai Method for treating suicidal ideation
US20160338977A1 (en) 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression
WO2017041112A1 (en) 2015-09-04 2017-03-09 Cyprus Therapeutics, Inc. Ketamine and cytochrome p 450 inhibitor combinations
WO2017087691A1 (en) 2015-11-17 2017-05-26 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
WO2017139382A1 (en) 2016-02-08 2017-08-17 The Texas A&M University System Combination of adjuvant drugs esketamine and brimonidine for medical treatments
US10034832B2 (en) 2016-02-12 2018-07-31 Synergistic Therapeutics, Llc Sublingual antidepressant lozenge
US20170266319A1 (en) 2016-03-21 2017-09-21 Children's Hospital Medical Center Methods and compositions for treating conditions associated with spinal cord injury
AU2017238858A1 (en) 2016-03-25 2018-10-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of using (2R, 6R)-hydroxynorketamine and (2S, 6S)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, fatigue, suicidal ideation, and post traumatic stress disorders
AU2017238859B2 (en) 2016-03-25 2021-02-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Crystal forms and methods of synthesis of (2R, 6R)-hydroxynorketamine and (2S, 6S)-hydroxynorketamine
GB2564990A (en) 2016-04-01 2019-01-30 Good Pharmaceutical Dev Company Llc Topical compositions for neuropathic pain
WO2017180589A1 (en) 2016-04-11 2017-10-19 Auspex Pharmaceuticals, Inc. Deuterated ketamine derivatives
US20170348252A1 (en) 2016-04-21 2017-12-07 Robert Kent Preparation and Use of Ketamine Derivatives and Ketamine Modifiers in the Treatment of Pain
CN109475500A (zh) 2016-05-25 2019-03-15 财团法人卫生研究院 用于减低氯胺酮致精神病状副作用及成瘾疾患的方法与组合物
US20190380978A1 (en) 2016-06-03 2019-12-19 Small Pharma Ltd Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof
US20200030251A1 (en) 2017-04-20 2020-01-30 Guangzhou Dazhou Biomedicine Ltd. Transdermal drug delivery system for ketamine

Also Published As

Publication number Publication date
JP6845162B2 (ja) 2021-03-17
US11191734B2 (en) 2021-12-07
AU2016288188A1 (en) 2018-01-04
CA2987909A1 (en) 2017-01-05
US20180353437A1 (en) 2018-12-13
EP3297620A1 (en) 2018-03-28
US20220193000A1 (en) 2022-06-23
CN107847469A (zh) 2018-03-27
HK1248578A1 (zh) 2018-10-19
KR20180021127A (ko) 2018-02-28
KR102299359B1 (ko) 2021-09-07
JP2018518498A (ja) 2018-07-12
EP3297620A4 (en) 2019-01-09
WO2017003935A1 (en) 2017-01-05
AU2016288188B2 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
US20220193000A1 (en) Ketamine transdermal delivery system
US20220395469A1 (en) Transdermal drug delivery system for ketamine
RU2408368C2 (ru) Препараты соли бупропиона с модифицированным высвобождением
JP6212104B2 (ja) オピエートアゴニスト及びアゴニスト−アンタゴニストの乱用抑止性経皮製剤
JP2023519959A5 (enExample)
US20210308040A1 (en) Ketamine oral transmucosal delivery system
KR20220161416A (ko) 덱스트로메토르판의 경피 전달
JP5073124B2 (ja) ノルアドレナリン作動性・特異的セロトニン作動性抗うつ薬含有経皮吸収型貼付製剤
EP2859892B1 (en) Patch
Gupta et al. Transdermal delivery: product and patent update
JP2022087276A (ja) メマンチン経皮送達システム
Abruzzo et al. Transdermal delivery of antipsychotics: rationale and current status
RU2504363C2 (ru) Усилитель чрескожного всасывания и трансдермальный препарат с его использованием
CN117545478A (zh) 用于治疗慢性疼痛的透皮药物制剂
EP3725306A1 (en) Transdermal therapeutic system
WO2009157586A1 (ja) フェンタニルまたはその塩含有経皮吸収型貼付剤
EP4192440B1 (en) Esketamine-suspension-tts
JP2010006761A (ja) フェンタニルまたはその塩を含有する経皮吸収型貼付剤およびその製造方法
HK40025664A (en) Transdermal drug delivery system for ketamine
JP2010030909A (ja) フェンタニル類を含む経皮吸収型貼付剤およびその製造方法ならびにフェンタニル類の結晶析出抑制方法および結晶析出抑制剤
KR101964295B1 (ko) 피부 자극이 감소된 메만틴 경피전달 시스템
HK40086503A (en) Esketamine-suspension-tts
HK40086503B (en) Esketamine-suspension-tts
JP2021102573A (ja) クエン酸フェンタニル含有経皮吸収製剤
JP2016216384A (ja) 経皮吸収型製剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210603

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251211

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260325

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260325